our mission
We invest, develop, and deliver breakthrough medicines
for genetic diseases to patients worldwide
our mission
We invest, develop, and deliver breakthrough medicines
for genetic diseases to patients worldwide
We invest, develop, and deliver breakthrough medicines
for genetic diseases to patients worldwide
We invest, develop, and deliver breakthrough medicines
for genetic diseases to patients worldwide
A confluence of breakthroughs in patient-oriented research, genome sequencing, chemical biology, and patient registries give us the opportunity to make therapeutic leaps against genetic disease. AdimaBio finds great science where the mechanism of a disease is well-understood and develops medicines that target those diseases at their source.
We are working to create clinical translation oriented biotech companies to advance multiple individual therapies simultaneously. Our decentralized subsidiary model lets us distribute shared central resources while remaining hyper-focused on developing therapies for each genetic disease.
Our investment model creates efficiency and scale, empowering our teams to make objective, data-driven decisions quickly across multiple programs. In just two years, AdimaBio has more than 3 clinical stage drug programs for genetic diseases - which we believe reduces the traditional biopharma process by years.
Cambridge, Massachusetts, United States
Copyright © 2021 AdimaBio - All Rights Reserved.
Powered by GoDaddy Website Builder